Ipsen Just Bet $1.75 Billion on a Drug That Doesn't Have Data Yet
Ipsen is paying up to $1.7 billion for Kartos Therapeutics and its myelofibrosis drug navtemadlin, but the pivotal trial data won't arrive until 2027. With Novartis, GSK, and AbbVie all circling the same disease, the race to dethrone ruxolitinib monotherapy is officially on.
Imagine buying a house sight unseen, based entirely on the floor plan and the neighborhood comps. That's roughly what Ipsen just did.
The French pharma company announced Sunday that it's acquiring Kartos Therapeutics, a U.S. biotech, in a deal worth up to $1.75 billion. The catch? The lead drug hasn't finished its pivotal trial. Top-line results won't arrive until 2027. And Ipsen won't see a profit from this deal until 2029 at the earliest.
So why write the check now? Because the myelofibrosis market is on fire, and Ipsen doesn't want to get locked out.
A Deal Built on "Ifs"
The structure tells you everything about the risk here. Ipsen is paying $450 million upfront in cash at closing. That's the guaranteed part. The remaining $1.3 billion comes in milestone payments, triggered only if the drug gets regulatory approval and hits certain sales targets.
Translation: about 74% of the deal's value is contingent on things that haven't happened yet. This is classic biotech dealmaking. The buyer limits downside; the seller gets rewarded if the science works out. Think of it like a sports contract loaded with performance bonuses.
The transaction should close by the end of Q3 2026, pending antitrust clearance. RBC Capital reiterated its Outperform rating on Ipsen after the announcement, calling it a strategic, de-risked oncology add-on that fits the company's preference for late-stage assets. Ipsen's stock ticked up, too, which suggests investors aren't spooked.
Meet Navtemadlin, the Drug at the Center of It All
Kartos's lead asset is navtemadlin (KRT-232), an oral pill designed to treat myelofibrosis, a rare blood cancer where scar tissue builds up in the bone marrow and disrupts normal blood cell production. Think of your bone marrow like a factory. In myelofibrosis, the factory floor gets clogged with fibrosis, and production grinds down.
The drug works by targeting something called MDM2, a protein that essentially acts as a bodyguard for cancer cells. MDM2 blocks , which is one of the body's most important tumor-suppressing proteins. Navtemadlin takes out the bodyguard, letting p53 do its job: triggering cancer cell death.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
p53
There's an important caveat, though. This mechanism only works in patients whose TP53 gene is still functioning normally (called "wild-type"). If TP53 is mutated, there's no p53 to rescue. So navtemadlin is designed for a specific slice of the myelofibrosis population.
The Trial That Will Make or Break the Bet
The big study is called POIESIS, a Phase 3 trial enrolling over 600 patients across more than 250 sites worldwide. It's testing navtemadlin as an add-on to ruxolitinib (sold as Jakafi by Incyte), the blockbuster drug that's been the backbone of myelofibrosis treatment since 2011.
The trial specifically targets patients who started ruxolitinib but had a suboptimal response, meaning the drug helped, but not enough. These patients stay on ruxolitinib and either get navtemadlin or a placebo on top.
POIESIS is expected to wrap up data collection by the end of 2026, with top-line results in 2027. If things go well, a launch could come around 2028, and Ipsen expects the deal to become accretive to its core operating income starting in 2029.
That's a long runway. But the early-stage data gives reason for cautious optimism.
The Phase 2 Breadcrumbs
In a small Phase 1b/2 study (19 patients), navtemadlin plus ruxolitinib showed some encouraging signals at 24 weeks. About 32% of patients hit a key spleen-shrinkage benchmark called SVR35, which is the standard bar used in myelofibrosis trials. Another 42% achieved at least a 25% reduction in spleen volume.
On the symptom side, 32% of patients saw their symptom scores cut in half or more. That's meaningful for a disease where fatigue, night sweats, and bone pain can be debilitating.
Perhaps the most intriguing finding: in the Phase 1b/2 add-on study, 71% of the 7 evaluable patients showed a significant reduction in the genetic mutations driving their cancer. And 57% saw improvement in their bone marrow fibrosis. Those hints at "disease modification" are what got Ipsen excited, because most current treatments manage symptoms without actually changing the course of the disease.
Small trial, big caveats. But the signal was strong enough to justify a 600-patient Phase 3.
Why Myelofibrosis Is Suddenly a Hot Market
Ipsen isn't the first company to go shopping in myelofibrosis, and it won't be the last. The M&A activity in this space over the past few years has been remarkable.
Novartis paid roughly $2.9 billion for MorphoSys in 2024, largely to get its hands on pelabresib, a BET inhibitor being tested in combination with ruxolitinib. Before that, MorphoSys itself had acquired Constellation Pharmaceuticals for $1.7 billion to get pelabresib in the first place. That drug has essentially been sold twice for blockbuster prices.
GSK spent $1.9 billion on Sierra Oncology to acquire momelotinib, another JAK inhibitor now approved for myelofibrosis patients with significant anemia. And in late 2024, Takeda licensed elritercept from Keros Therapeutics for myelofibrosis-related anemia.
The pattern is clear: big pharma is circling myelofibrosis like it's the last open parking spot at Costco on a Saturday.
The Problem Everyone Is Trying to Solve
Here's why. Ruxolitinib has been the standard of care for over a decade, and it does a decent job shrinking spleens and easing symptoms. But it doesn't cure the disease. It doesn't reverse the fibrosis. And for many patients, it eventually stops working.
Four JAK inhibitors are now approved in the U.S.: ruxolitinib, fedratinib, pacritinib, and momelotinib. Doctors pick among them based on a patient's specific blood count issues. But none of them fundamentally change the disease trajectory. Patients who fail JAK inhibitors face bleak options. Many progress to an aggressive form of leukemia.
That's the gap everyone is racing to fill. The entire myelofibrosis field is converging on a single question: can we add a second drug to ruxolitinib that actually modifies the disease, not just the symptoms?
Navtemadlin is one answer. Pelabresib (now Novartis's baby) is another. AbbVie's navitoclax is a third. Each uses a different mechanism. The one that proves superiority in a Phase 3 trial will likely become the new standard of care.
Ipsen's Bigger Play
This deal also makes sense when you zoom out on Ipsen's strategy. The company has been on an acquisition spree, adding over 30 programs since 2020 and 8 new assets in 2024 alone across oncology, rare disease, and neuroscience.
In hematology specifically, Ipsen acquired ImCheck Therapeutics to get IPN60340, a first-in-class antibody in early trials for acute myeloid leukemia. Adding navtemadlin gives Ipsen a second blood cancer program, this one much further along in development.
Ipsen has been vocal about prioritizing external innovation as its top capital-allocation priority. The Kartos deal, with its modest $450 million upfront price tag, leaves plenty of room for more shopping.
The Scoreboard
Let's put Ipsen's deal in context against the competition:
Novartis/MorphoSys (pelabresib): ~$2.9 billion
GSK/Sierra Oncology (momelotinib): $1.9 billion
Ipsen/Kartos (navtemadlin): up to $1.75 billion ($450M upfront)
Ipsen's deal is the most back-loaded of the bunch, which makes sense given the Phase 3 data gap. Novartis and GSK paid steeper upfront premiums because their targets had more clinical data in hand.
What Happens Next
Everything hinges on 2027. If POIESIS delivers strong efficacy data (particularly on spleen volume reduction, symptom improvement, and those tantalizing disease-modification signals), Ipsen will look like a genius buying Kartos before the results dropped.
If the trial misses? That $450 million becomes an expensive lesson, and the $1.3 billion in milestones never gets paid. Ipsen walks away bruised but not broken.
For myelofibrosis patients, the stakes are much higher. They need something better than what's available today, and the race between navtemadlin, pelabresib, navitoclax, and others could finally deliver it. The next 18 months will tell us which horse crosses the finish line first.
5 min read
Lilly's Quiet Move to Win the GLP-1 Price War
Eli Lilly just made every dose of Zepbound available for $499 or less per month, completing a pricing strategy that's quietly reshaping the GLP-1 obesity market. The move intensifies a price war with Novo Nordisk while exposing just how broken insurance coverage for weight-loss drugs remains.
